Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Patent metadata

Field	Value
Publication number	US-11084884-B2
Application number	US-201515113297-A
Country	US
Kind code	B2
Filing date	Jan 21, 2015
Priority date	Jan 21, 2014
Publication date	Aug 10, 2021
Grant date	Aug 10, 2021

Abstract

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

First claim

What is claimed is:

1. A method of treating hereditary angioedema (HAE), the method comprising:
administering to a subject in need thereof an antibody in an effective amount of 300 mg or 400 mg every two weeks or every four weeks, wherein the antibody comprises:
a heavy chain CDR1 comprising HYIMM (SEQ ID NO:5);
a heavy chain CDR2 comprising GIYSSGGITVYADSVKG (SEQ ID NO:6);
a heavy chain CDR3 comprising RRIGVPRRDEFDI (SEQ ID NO:7);
a light chain CDR1 comprising RASQSISSWLA (SEQ ID NO:8);
a light chain CDR2 comprising KASTLES (SEQ ID NO:9); and
a light chain CDR3 comprising QQYNTYWT (SEQ ID NO:10).

2. The method of claim 1 , wherein the antibody is a full length antibody or an antigen-binding fragment thereof.

3. The method of claim 2 , wherein the antibody is DX-2930.

4. The method of claim 1 , wherein the antibody is administered at 300 mg every two weeks.

5. The method of claim 1 , wherein the antibody is administered at 300 mg every four weeks.

6. The method of claim 1 , wherein the antibody is administered subcutaneously.

7. The method of claim 1 , wherein the subject is a human patient having, suspected of having, or at risk for HAE.

8. The method of claim 1 , wherein the antibody is administered for prophylactic treatment.

9. The method of claim 1 , further comprising monitoring the level of creatine phosphokinase in the subject before and after the treatment, or during the course of the treatment.

10. The method of claim 9 , further comprising reducing the dose of the antibody or terminating the treatment if creatine phosphokinase elevation is observed.

11. The method of claim 1 , wherein the antibody is an IgG1.

12. The method of claim 1 , wherein the antibody comprises a heavy chain variable region comprising the sequence of SEQ ID NO:3 and a light chain variable region comprising the sequence of SEQ ID NO:4.

13. The method of claim 4 , wherein the antibody comprises a heavy chain variable region comprising the sequence of SEQ ID NO:3 and a light chain variable region comprising the sequence of SEQ ID NO:4.

14. The method of claim 5 , wherein the antibody comprises a heavy chain variable region comprising the sequence of SEQ ID NO:3 and a light chain variable region comprising the sequence of SEQ ID NO:4.

15. The method of claim 1 , wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:1 and a light chain comprising the sequence of SEQ ID NO:2.

16. The method of claim 4 , wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:1 and a light chain comprising the sequence of SEQ ID NO:2.

17. The method of claim 5 , wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:1 and a light chain comprising the sequence of SEQ ID NO:2.

Assignees

• Takeda Pharmaceuticals Co

Inventors

• Sexton Daniel J
• Adelman Burt
• Chyung Yung
• Tenhoor Christopher
• Kenniston Jon A
• Faucette Ryan
• Iarrobino Ryan
• Biedenkapp Joseph

Classifications

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K16/40 Primary

  against enzymes · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P7/10

  Antioedematous agents; Diuretics · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title